Literature DB >> 21145762

Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice.

Madhav D Sharma1, De-Yan Hou, Babak Baban, Pandelakis A Koni, Yukai He, Phillip R Chandler, Bruce R Blazar, Andrew L Mellor, David H Munn.   

Abstract

Foxp3(+) regulatory T (Treg) cells can undergo reprogramming into a phenotype expressing proinflammatory cytokines. However, the biologic significance of this conversion remains unclear. We show that large numbers of Treg cells undergo rapid reprogramming into activated T helper cells after vaccination with antigen plus Toll-like receptor 9 (TLR-9) ligand. Helper activity from converted Treg cells proved essential during initial priming of CD8(+) T cells to a new cross-presented antigen. Help from Treg cells was dependent on CD40L, and (unlike help from conventional non-Treg CD4(+) cells) did not require preactivation or prior exposure to antigen. In hosts with established tumors, Treg cell reprogramming was suppressed by tumor-induced indoleamine 2,3-dioxygenase (IDO) and vaccination failed because of lack of help. Treg cell reprogramming, vaccine efficacy, and antitumor CD8(+) T cell responses were restored by pharmacologic inhibition of IDO. Reprogrammed Treg cells can thus participate as previously unrecognized drivers of certain early CD8(+) T cell responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21145762      PMCID: PMC3032429          DOI: 10.1016/j.immuni.2010.11.022

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  29 in total

1.  Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Science       Date:  2003-01-16       Impact factor: 47.728

2.  Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection.

Authors:  Benoît Vokaer; Nicolas Van Rompaey; Philippe H Lemaître; Frédéric Lhommé; Carole Kubjak; Fleur S Benghiat; Yoichiro Iwakura; Michel Petein; Kenneth A Field; Michel Goldman; Alain Le Moine; Louis-Marie Charbonnier
Journal:  J Immunol       Date:  2010-08-23       Impact factor: 5.422

3.  Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.

Authors:  Jacqueline D Shields; Iraklis C Kourtis; Alice A Tomei; Joanna M Roberts; Melody A Swartz
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

4.  Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection.

Authors:  Guillaume Oldenhove; Nicolas Bouladoux; Elizabeth A Wohlfert; Jason A Hall; David Chou; Liliane Dos Santos; Shaun O'Brien; Rebecca Blank; Erika Lamb; Sundar Natarajan; Robin Kastenmayer; Christopher Hunter; Michael E Grigg; Yasmine Belkaid
Journal:  Immunity       Date:  2009-11-05       Impact factor: 31.745

Review 5.  Plasticity of CD4(+) FoxP3(+) T cells.

Authors:  Xuyu Zhou; Samantha Bailey-Bucktrout; Lukas T Jeker; Jeffrey A Bluestone
Journal:  Curr Opin Immunol       Date:  2009-06-06       Impact factor: 7.486

6.  Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help.

Authors:  S R Bennett; F R Carbone; F Karamalis; J F Miller; W R Heath
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

7.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

8.  CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.

Authors:  P A Taylor; R J Noelle; B R Blazar
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

9.  Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state.

Authors:  Sylvain Fisson; Guillaume Darrasse-Jèze; Elena Litvinova; Franck Septier; David Klatzmann; Roland Liblau; Benoît L Salomon
Journal:  J Exp Med       Date:  2003-08-25       Impact factor: 14.307

10.  Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.

Authors:  Xuyu Zhou; Samantha L Bailey-Bucktrout; Lukas T Jeker; Cristina Penaranda; Marc Martínez-Llordella; Meredith Ashby; Maki Nakayama; Wendy Rosenthal; Jeffrey A Bluestone
Journal:  Nat Immunol       Date:  2009-07-26       Impact factor: 25.606

View more
  95 in total

1.  Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.

Authors:  Courtney A Crane; Brian J Ahn; Seunggu J Han; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

Review 2.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

Review 3.  Highlights of 10 years of immunology in Nature Reviews Immunology.

Authors:  Ruslan Medzhitov; Ethan M Shevach; Giorgio Trinchieri; Andrew L Mellor; David H Munn; Siamon Gordon; Peter Libby; Göran K Hansson; Ken Shortman; Chen Dong; Dmitry Gabrilovich; Leona Gabryšová; Ashleigh Howes; Anne O'Garra
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

Review 4.  Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors:  Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

5.  Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals.

Authors:  Laura Pattacini; Pamela M Murnane; Erin M Kahle; Michael J Bolton; Jeffrey J Delrow; Jairam R Lingappa; Elly Katabira; Deborah Donnell; M Juliana McElrath; Jared M Baeten; Jennifer M Lund
Journal:  AIDS Res Hum Retroviruses       Date:  2013-07-30       Impact factor: 2.205

Review 6.  Targeted antigen delivery to DEC-205⁺ dendritic cells for tolerogenic vaccination.

Authors:  Cathleen Petzold; Sonja Schallenberg; Joel N H Stern; Karsten Kretschmer
Journal:  Rev Diabet Stud       Date:  2012-12-28

7.  The regulatory T cells in anti-influenza antibody response post influenza vaccination.

Authors:  Shih-Min Wang; Ming-Hsun Tsai; Huan-Yao Lei; Jen-Ren Wang; Ching-Chuan Liu
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

8.  Physiologic control of IDO competence in splenic dendritic cells.

Authors:  Babak Baban; Phillip R Chandler; Burles A Johnson; Lei Huang; Minghui Li; Marlon L Sharpe; Loise M Francisco; Arlene H Sharpe; Bruce R Blazar; David H Munn; Andrew L Mellor
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

9.  In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

Authors:  K L Hippen; R S O'Connor; A M Lemire; A Saha; E A Hanse; N C Tennis; S C Merkel; A Kelekar; J L Riley; B L Levine; C H June; L A Turka; L S Kean; M L MacMillan; J S Miller; J E Wagner; D H Munn; B R Blazar
Journal:  Am J Transplant       Date:  2017-06-14       Impact factor: 8.086

10.  Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors.

Authors:  Brendan T Parr; Richard Pastor; Benjamin D Sellers; Zhonghua Pei; Firoz A Jaipuri; Georgette M Castanedo; Lewis Gazzard; Sanjeev Kumar; Xiaokai Li; Wen Liu; Rohan Mendonca; Roheeth K Pavana; Hima Potturi; Cheng Shao; Venkata Velvadapu; Jesse P Waldo; Guosheng Wu; Po-Wai Yuen; Zuhui Zhang; Yamin Zhang; Seth F Harris; Angela J Oh; Antonio DiPasquale; Kevin Dement; Hank La; Leanne Goon; Amy Gustafson; Erica C VanderPorten; Mario R Mautino; Yichin Liu
Journal:  ACS Med Chem Lett       Date:  2020-03-04       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.